AU768405B2 - Regulation of HER2/neu oncongene expression by synthetic polyamides - Google Patents

Regulation of HER2/neu oncongene expression by synthetic polyamides Download PDF

Info

Publication number
AU768405B2
AU768405B2 AU60341/99A AU6034199A AU768405B2 AU 768405 B2 AU768405 B2 AU 768405B2 AU 60341/99 A AU60341/99 A AU 60341/99A AU 6034199 A AU6034199 A AU 6034199A AU 768405 B2 AU768405 B2 AU 768405B2
Authority
AU
Australia
Prior art keywords
polyamide
her2
polyamides
neu
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU60341/99A
Other languages
English (en)
Other versions
AU6034199A (en
Inventor
Peter Dervan
Joel M Gottesfeld
John J. Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
Scripps Research Institute
Original Assignee
California Institute of Technology CalTech
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech, Scripps Research Institute filed Critical California Institute of Technology CalTech
Publication of AU6034199A publication Critical patent/AU6034199A/en
Application granted granted Critical
Publication of AU768405B2 publication Critical patent/AU768405B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU60341/99A 1998-09-11 1999-09-10 Regulation of HER2/neu oncongene expression by synthetic polyamides Ceased AU768405B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9990698P 1998-09-11 1998-09-11
US60/099906 1998-09-11
PCT/US1999/020840 WO2000015209A2 (en) 1998-09-11 1999-09-10 REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES

Publications (2)

Publication Number Publication Date
AU6034199A AU6034199A (en) 2000-04-03
AU768405B2 true AU768405B2 (en) 2003-12-11

Family

ID=22277188

Family Applications (2)

Application Number Title Priority Date Filing Date
AU60341/99A Ceased AU768405B2 (en) 1998-09-11 1999-09-10 Regulation of HER2/neu oncongene expression by synthetic polyamides
AU64965/99A Abandoned AU6496599A (en) 1998-09-11 1999-09-10 Regulation of her2/neu oncogene expression by synthetic polyamides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU64965/99A Abandoned AU6496599A (en) 1998-09-11 1999-09-10 Regulation of her2/neu oncogene expression by synthetic polyamides

Country Status (5)

Country Link
EP (2) EP1162961A2 (ja)
JP (2) JP2002524501A (ja)
AU (2) AU768405B2 (ja)
CA (2) CA2344654A1 (ja)
WO (2) WO2000015209A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010368A1 (fr) * 2000-07-21 2002-02-07 Chiba Prefecture Promoteurs specifiques de tumeur
US7122626B2 (en) 2001-04-26 2006-10-17 Genesoft Pharmceuticals, Inc. Halogen-substitued thienyl compounds
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
WO2002101007A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc Antipathogenic benzamide compounds
US6825228B2 (en) 2001-06-13 2004-11-30 Genesoft Pharmaceuticals, Inc. Benzothiophene compounds having antiinfective activity
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
US7498349B2 (en) 2002-08-02 2009-03-03 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
AU2003285958A1 (en) 2002-10-25 2004-05-25 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
CA2508769A1 (en) 2002-12-10 2004-06-24 Oscient Pharmaceuticals Corporation Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
JP3792655B2 (ja) 2003-01-20 2006-07-05 日本電気株式会社 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途
JP2006022063A (ja) * 2004-07-09 2006-01-26 Univ Nihon Ｌｏｘ−１遺伝子発現抑制剤
EP3503898A1 (en) * 2016-08-29 2019-07-03 California Institute of Technology Compositions and methods for treatment of prostate cancer
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035702A1 (en) * 1996-08-01 1998-08-20 California Institute Of Technology Inhibition of gene transcription by polyamide dna-binding ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035702A1 (en) * 1996-08-01 1998-08-20 California Institute Of Technology Inhibition of gene transcription by polyamide dna-binding ligands

Also Published As

Publication number Publication date
EP1162961A2 (en) 2001-12-19
WO2000015209A2 (en) 2000-03-23
WO2000015209A3 (en) 2000-05-25
WO2000015242A1 (en) 2000-03-23
JP2002524525A (ja) 2002-08-06
CA2344654A1 (en) 2000-03-23
EP1112080A1 (en) 2001-07-04
CA2343289A1 (en) 2000-03-23
AU6496599A (en) 2000-04-03
EP1112080A4 (en) 2002-10-24
JP2002524501A (ja) 2002-08-06
AU6034199A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
AU768405B2 (en) Regulation of HER2/neu oncongene expression by synthetic polyamides
JP2002515057A (ja) ポリアミドｄｎａ結合リガンドによる遺伝子発現の阻害
NZ524894A (en) Antisense oligonucleotides against VR1
JPH11236396A (ja) ペプチド核酸の高次構造および結合
WO2000015773A9 (en) Inhibition of oncogene transcription by synthetic polyamides
JP2021532784A (ja) アンチセンス送達のための三量体ペプチド
CA2342278A1 (en) Inhibition of oncogene transcription by synthetic polyamides
US6537973B1 (en) Oligonucleotide inhibition of protein kinase C
KR20210010362A (ko) 멜라노필린 안티센스 올리고뉴클레오티드
US20060019972A1 (en) Methods of treating cancer by inhibiting histone gene expression
MXPA01013114A (es) Conjugados y metodos para la produccion de los mismos, y su uso poara transportar moleculas a traves de membranas biologicas.
JP2002539077A (ja) 二本鎖核酸とのヌクレオチド塩基対−特異的相互作用を受ける環状化合物に関する組成物および方法
KR102304280B1 (ko) 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
US7935530B2 (en) Polyamides with tail structures capable of binding DNA
EP4049664A1 (en) Nucleic acid delivery enhancer
WO2021261592A1 (ja) リピート結合剤
AU2010202859A1 (en) Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs
WO1998049287A2 (en) Antisense oligonucleotides specific for thymidylate synthase
US20070048294A1 (en) Method for inhibiting telomerase activity
US20020173479A1 (en) Methods for the treatment and diagnosis of prostate cancer based on p75NTR tumor supression

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)